Public Health Preparedness and Response
FDA prepares to respond to a wide variety of natural and human-caused threats and public health emergencies (e.g., COVID-19) that involve, affect, or require the use of FDA-regulated products to help keep the public safe. FDA carries out many activities to protect and advance public health and to prevent and respond to public health emergencies.
In response to a public health emergency, FDA’s research amplifies the many regulatory activities that take place. This includes development of standards, panels, and reagents to help speed the development and availability of potential vaccines, diagnostics and therapeutics; maintaining and securing drug supply chains; expediting approval of generics to help alleviate drug shortages; providing guidance to food and medical device manufacturers; advising developers on clinical trial issues; and keeping the public informed with fact-based health information. FDA oversees the repurposing of existing drugs and the development and approval of new drugs and vaccines by working with potential manufacturers and sponsors to rapidly move products into clinical trials, while helping to ensure the trials are properly and safely designed.
FDA actively communicates in real-time with hospitals across the United States and external stakeholders about their drug supply needs. FDA builds capacity through partnerships, including the Laboratory Flexible Funding Model to increase chemical, radiological and microbiological resources for domestic partners to respond to public health events.
|Minority Health and Health Equity||Women’s Health||Maternal Health||Pediatric Health|
|Oncology||Rare Diseases||One Health Initiative|
Research Capabilities, Tools, and Resources
|Research Management and Collaborations||Technology Transfer and Public-Private Partnerships||Physical Standards and Reference Materials||Intramural Grant Programs||Extramural Funding Mechanisms|
Scientific Education, Training, and Communication
|Fellowship and Training Opportunities||Professional Development and Continuing Education||Communication and External Meetings|
|Facilities and Shared Resources||Safety and Compliance|
|Office of the Chief Scientist||Contact Us: FARS@fda.hhs.gov|